Compare Divis Laboratories with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs J.B.CHEMICALS - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES J.B.CHEMICALS DIVIS LABORATORIES/
J.B.CHEMICALS
 
P/E (TTM) x 59.2 33.1 178.8% View Chart
P/BV x 13.6 6.2 221.6% View Chart
Dividend Yield % 0.4 0.2 234.4%  

Financials

 DIVIS LABORATORIES   J.B.CHEMICALS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
J.B.CHEMICALS
Mar-18
DIVIS LABORATORIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,639363 451.5%   
Low Rs1,115255 437.3%   
Sales per share (Unadj.) Rs186.3169.1 110.2%  
Earnings per share (Unadj.) Rs51.016.6 307.0%  
Cash flow per share (Unadj.) Rs57.323.4 244.8%  
Dividends per share (Unadj.) Rs16.002.00 800.0%  
Dividend yield (eoy) %1.20.6 179.5%  
Book value per share (Unadj.) Rs261.8172.5 151.8%  
Shares outstanding (eoy) m265.4783.57 317.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x7.41.8 404.5%   
Avg P/E ratio x27.018.6 145.2%  
P/CF ratio (eoy) x24.013.2 182.0%  
Price / Book Value ratio x5.31.8 293.6%  
Dividend payout %31.412.0 260.6%   
Avg Mkt Cap Rs m365,59225,827 1,415.5%   
No. of employees `00011.83.8 314.1%   
Total wages/salary Rs m5,4232,511 216.0%   
Avg. sales/employee Rs Th4,175.13,747.4 111.4%   
Avg. wages/employee Rs Th457.7665.7 68.8%   
Avg. net profit/employee Rs Th1,141.8367.8 310.5%   
INCOME DATA
Net Sales Rs m49,46314,135 349.9%  
Other income Rs m1,556366 425.5%   
Total revenues Rs m51,01914,501 351.8%   
Gross profit Rs m18,7182,178 859.3%  
Depreciation Rs m1,689570 296.5%   
Interest Rs m3535 100.3%   
Profit before tax Rs m18,5511,940 956.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023552 909.5%   
Profit after tax Rs m13,5271,387 975.2%  
Gross profit margin %37.815.4 245.6%  
Effective tax rate %27.128.5 95.1%   
Net profit margin %27.39.8 278.7%  
BALANCE SHEET DATA
Current assets Rs m46,50110,470 444.1%   
Current liabilities Rs m8,4682,749 308.0%   
Net working cap to sales %76.954.6 140.8%  
Current ratio x5.53.8 144.2%  
Inventory Days Days13155 237.0%  
Debtors Days Days8678 110.6%  
Net fixed assets Rs m25,7975,811 443.9%   
Share capital Rs m531167 317.7%   
"Free" reserves Rs m68,96214,248 484.0%   
Net worth Rs m69,49314,416 482.1%   
Long term debt Rs m00-   
Total assets Rs m80,38317,649 455.5%  
Interest coverage x531.056.6 938.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.8 76.8%   
Return on assets %16.98.1 209.4%  
Return on equity %19.59.6 202.3%  
Return on capital %26.713.7 195.3%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,2386,164 669.0%   
Fx outflow Rs m12,4051,334 929.6%   
Net fx Rs m28,8334,829 597.0%   
CASH FLOW
From Operations Rs m9,5431,231 775.5%  
From Investments Rs m-6,854-208 3,293.6%  
From Financial Activity Rs m-2,459-595 413.2%  
Net Cashflow Rs m230427 53.8%  

Share Holding

Indian Promoters % 52.0 55.4 93.9%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 11.8 3.4 348.1%  
FIIs % 19.0 3.9 487.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 37.0 46.5%  
Shareholders   31,796 30,437 104.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON   IPCA LABS  JUBILANT LIFE SCIENCES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (3QFY20); Net Profit Up 34.1% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 25, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ASTRAZENECA PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS